- Home
- CMAX vs BCDA Comparison
CMAX vs BCDA Comparison
Compare CMAX & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- BCDA
- Stock Information
- Founded
- CMAX 2011
- BCDA N/A
- Country
- CMAX United States
- BCDA United States
- Employees
- CMAX N/A
- BCDA N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CMAX Technology
- BCDA Health Care
- Exchange
- CMAX Nasdaq
- BCDA Nasdaq
- Market Cap
- CMAX 7.6M
- BCDA 7.9M
- IPO Year
- CMAX N/A
- BCDA N/A
- Fundamental
- Price
- CMAX $1.85
- BCDA $2.68
- Analyst Decision
- CMAX Hold
- BCDA Strong Buy
- Analyst Count
- CMAX 2
- BCDA 1
- Target Price
- CMAX $33.20
- BCDA $25.00
- AVG Volume (30 Days)
- CMAX 58.0K
- BCDA 73.1K
- Earning Date
- CMAX 11-07-2024
- BCDA 11-06-2024
- Dividend Yield
- CMAX N/A
- BCDA N/A
- EPS Growth
- CMAX N/A
- BCDA N/A
- EPS
- CMAX N/A
- BCDA N/A
- Revenue
- CMAX $784,551,000.00
- BCDA $428,000.00
- Revenue This Year
- CMAX $13.01
- BCDA $6.92
- Revenue Next Year
- CMAX $32.42
- BCDA N/A
- P/E Ratio
- CMAX N/A
- BCDA N/A
- Revenue Growth
- CMAX 9.06
- BCDA 0.71
- 52 Week Low
- CMAX $1.55
- BCDA $1.96
- 52 Week High
- CMAX $74.70
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- CMAX 46.01
- BCDA 49.01
- Support Level
- CMAX $1.60
- BCDA $2.39
- Resistance Level
- CMAX $2.39
- BCDA $2.90
- Average True Range (ATR)
- CMAX 0.19
- BCDA 0.18
- MACD
- CMAX 0.07
- BCDA -0.00
- Stochastic Oscillator
- CMAX 32.50
- BCDA 53.70
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).